Eledon Pharmaceuticals, Inc. lost $0.52 per diluted share in fiscal year 2025. Over the trailing 12 months, Q3 FY2025 through Q2 FY2026, the same line adds up to a loss of $0.91 per diluted share. The table below carries 14 fiscal years, from 2012 to 2025, and the quarters Eledon Pharmaceuticals, Inc. has filed alongside them.
FY2025 annual
EPS (Diluted)-$0.52
Source SEC Filings (10-K/10-Q)Latest period Q2 FY2026, ended Jun 30, 2026ReportedCurrency USD
Annual figures, oldest first. Point at a bar to read its period.
ELDN EPS (Diluted) by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.
What was Eledon Pharmaceuticals, Inc.'s diluted earnings per share in fiscal year 2025?
Eledon Pharmaceuticals, Inc. lost $0.52 per diluted share in fiscal year 2025.
What is Eledon Pharmaceuticals, Inc.'s diluted earnings per share over the last twelve months?
Eledon Pharmaceuticals, Inc. (ELDN) reported a loss of $0.91 per diluted share over the trailing 12 months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
How has Eledon Pharmaceuticals, Inc.'s diluted earnings per share changed over the years?
Across the 14 fiscal years this page covers, Eledon Pharmaceuticals, Inc. (ELDN) diluted earnings per share went from -$31.09 in fiscal year 2012 to -$0.52 in fiscal year 2025.
What was Eledon Pharmaceuticals, Inc.'s diluted earnings per share in the most recent quarter?
Eledon Pharmaceuticals, Inc. (ELDN) reported -$0.27 in diluted earnings per share in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
What does diluted earnings per share mean on a financial statement?
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what Eledon Pharmaceuticals, Inc. (ELDN) reported on that line in every period on record.
